These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12486962)

  • 21. Study inclusion criteria and presentation of results in a meta-analysis of granulocyte colony-stimulating factor for prevention of febrile neutropenia.
    Lathia N; Isogai PK; Cheung MC; Mittmann N
    J Clin Oncol; 2010 Dec; 28(36):e762-3; author reply e764. PubMed ID: 21079143
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Guidelines for prevention of febrile neutropenia].
    Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
    Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
    Watanabe T
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The dilemma of stimulating factors in the recovery from chemotherapeutic neutropenia].
    Borbollo Escoboza JR; González Avante M; Alvarado Ibarra M
    Rev Invest Clin; 1996; 48(4):328. PubMed ID: 8966397
    [No Abstract]   [Full Text] [Related]  

  • 28. Colony-stimulating factor use in the context of refined risk and benefit assessments.
    Crawford J
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):9-10. PubMed ID: 16736982
    [No Abstract]   [Full Text] [Related]  

  • 29. [Granulocyte transfusions. Return to the past].
    Muncunill J
    Med Clin (Barc); 1999 May; 112(15):574-6. PubMed ID: 10365384
    [No Abstract]   [Full Text] [Related]  

  • 30. Colony-stimulating factors stimulate some treatments, continue to evolve.
    Volkers N
    J Natl Cancer Inst; 1999 Feb; 91(3):210-2. PubMed ID: 10037097
    [No Abstract]   [Full Text] [Related]  

  • 31. Myeloid growth factors should not be administered routinely after allogeneic hematopoietic stem-cell transplantation.
    Mehta J
    J Clin Oncol; 2004 Nov; 22(21):4429-30; author reply 4430-2. PubMed ID: 15514388
    [No Abstract]   [Full Text] [Related]  

  • 32. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
    Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
    J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of myelosuppression by combined treatment with enterosorbent and granulocyte colony-stimulating factor.
    Shevchuk OO; Posokhova КА; Todor IN; Lukianova NY; Nikolaev VG; Chekhun VF
    Exp Oncol; 2015 Jun; 37(2):135-8. PubMed ID: 26112942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
    Ribas A; Albanell J; Bellmunt J; Solé-Calvo LA
    J Natl Cancer Inst; 1997 Mar; 89(5):395-6. PubMed ID: 9060963
    [No Abstract]   [Full Text] [Related]  

  • 36. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.
    Wingard JR; Elmongy M
    Crit Rev Oncol Hematol; 2009 Nov; 72(2):144-54. PubMed ID: 19237297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of granulocyte colony-stimulating factor (G-CSF) on the activity of granulocyte enzymes in children with cancer who developed neutropenia after chemotherapy.
    Czygier M; Dakowicz L; Szmitkowski M
    Adv Med Sci; 2008; 53(2):278-82. PubMed ID: 18614436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
    Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
    J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis.
    Wang J; An L; Chen S; Ouyang J; Zhou R; Chen B; Yang Y
    Acta Haematol; 2009; 121(4):223-6. PubMed ID: 19546524
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.